Palatin Technologies Inc (PTN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Palatin Technologies Inc (PTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10062
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company’s development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its clinical pipeline includes melanocortin receptor programs such as Bremelanotide MC4r Agonist for hypoactive sexual desire disorder, PL-8177 MC1r Agonist for inflammatory bowel disease and PL-8331 MC1/5r Agonist for anti-inflammatory ocular indications; and natriuretic peptide receptor programs including PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.

Palatin Technologies Inc (PTN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11
Licensing Agreements 12
Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14
Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16
Equity Offering 17
Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17
Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18
Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19
Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21
Palatin Raises USD20 Million in Private Placement of Warrants 23
Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25
Palatin Technologies Completes Private Placement Of Common Stock And Warrants For US$35 Million 27
Palatin Technologies Inc – Key Competitors 28
Palatin Technologies Inc – Key Employees 29
Palatin Technologies Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 13, 2018: Palatin Technologies reports fourth quarter and fiscal year 2018 results 31
May 15, 2018: Palatin Technologies Announces Third Quarter Fiscal Year 2018 Results 34
Feb 12, 2018: Palatin Technologies Reports Second Quarter Fiscal Year 2018 Results 36
Nov 13, 2017: Palatin Technologies reports first quarter fiscal year 2018 results 38
Sep 25, 2017: Palatin Technologies Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 40
May 16, 2017: Palatin Technologies Reports Third Quarter Fiscal Year 2017 Results 42
Feb 09, 2017: Palatin Technologies Reports Second Quarter Fiscal Year 2017 Results 44
Corporate Communications 45
Sep 12, 2017: Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors 45
Product News 46
01/03/2018: Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis 46
Product Approvals 47
Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide 47
Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA 49
Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women 50
Clinical Trials 51
May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 51
May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts 52
Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease 53
Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist 54
Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting 55
Other Significant Developments 57
Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 57
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Palatin Secures USD10 Million Venture Loan from Horizon Technology Finance 11
Kwang Dong Pharma Enters into Licensing Agreement with Palatin Technologies 12
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 13
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 14
Palatin Exercises Option For Licensing Agreement With European Specialty Pharmaceutical Company 16
Palatin Technologies Plans to Raise USD100 Million in Public Offering of Securities 17
Palatin Technologies Plans to Raise up to USD25 Million in Public Offering of Shares 18
Palatin Technologies Raises USD16.5 Million in Public Offering of Units 19
Palatin Technologies Raises USD9.2 Million in Public Offering of Units 21
Palatin Raises USD20 Million in Private Placement of Warrants 23
Palatin Raises USD20 Million in Private Placement of Shares and Warrants 25
Palatin Technologies Completes Private Placement Of Common Stock And Warrants For US$35 Million 27
Palatin Technologies Inc, Key Competitors 28
Palatin Technologies Inc, Key Employees 29
Palatin Technologies Inc, Subsidiaries 30

List of Figures
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Palatin Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Palatin Technologies Inc (PTN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Distilleries Company of Sri Lanka PLC:戦略・SWOT・企業財務分析
    Distilleries Company of Sri Lanka PLC - Strategy, SWOT and Corporate Finance Report Summary Distilleries Company of Sri Lanka PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • bioMerieux SA (BIM)-医療機器分野:企業M&A・提携分析
    Summary bioMerieux S.A. (bioMerieux) designs, develops and manufactures diagnostic systems and reagents for physicians and biologists. The company offers diagnostic solutions such as instruments, reagents and software. bioMerieux products are used diagnosing and managing infectious diseases, cardiov …
  • InVivoScribe Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent development products. It also provides general purpose reagents such as PCR …
  • TransGenic Inc (2342):企業の財務・戦略的SWOT分析
    TransGenic Inc (2342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • West Cornwall Pasty Co. Ltd:企業の戦略・SWOT・財務分析
    West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report Summary West Cornwall Pasty Co. Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Weyerhaeuser Company:企業の戦略・SWOT・財務情報
    Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report Summary Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Shelby Energy Cooperative, Inc.:企業の戦略的SWOT分析
    Shelby Energy Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • CMP Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • Sempra Energy (SRE):石油・ガス:M&Aディール及び事業提携情報
    Summary Sempra Energy (Sempra) is an energy-services holding company. Through its subsidiaries, the company invests in, develops, and operates energy infrastructure. It carries out utility operations, development of energy infrastructure and related services in countries including the US, Mexico, Ar …
  • Natera Inc (NTRA):医療機器:M&Aディール及び事業提携情報
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …
  • M3 Biotechnology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary M3 Biotechnology Inc (M3 Biotech) is a clinical stage biotech company that focuses on regenerative medicine. The company is developing clinical programs for the treatment of Alzheimer, MS, Parkinson and Alzheimerdisease (oral) among others. It utilizes discovery platform and develops small m …
  • Success Universe Group Limited:企業の戦略・SWOT・財務分析
    Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report Summary Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • PICC Property and Casualty Co Ltd:企業の戦略・SWOT・財務情報
    PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report Summary PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Fastenal Co:企業の戦略・SWOT・財務分析
    Fastenal Co - Strategy, SWOT and Corporate Finance Report Summary Fastenal Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Central Asia Metals PLC:企業の戦略・SWOT・財務情報
    Central Asia Metals PLC - Strategy, SWOT and Corporate Finance Report Summary Central Asia Metals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China North Industries Corporation:企業の戦略・SWOT・財務情報
    China North Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary China North Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Pearl Global Industries Limited:企業の戦略・SWOT・財務情報
    Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Vistin Pharma AS (VISTIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies active pharmaceutical ingredients and solid dosage forms. The company’s products include opioids, an analgesics and antitussive; metformin, an API for the treatment of diabetes II; …
  • Samsung C&T Corporation:企業の戦略・SWOT・財務情報
    Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report Summary Samsung C&T Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • mixi, Inc.:企業の戦略・SWOT・財務情報
    mixi, Inc. - Strategy, SWOT and Corporate Finance Report Summary mixi, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆